Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. (February 2009)

• Record Type: Journal Article
• Authors: Borghaei, Hossein; Mehra, Ranee; Simon, George
• Is Part Of: Future oncology. Volume 5:Number 1(2009)
• Page Start: 19
• Page End: 22
• Publication Date: 2009-02
• Subjects: adjuvant chemotherapy -- carboplatin -- lung cancer -- paclitaxel; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/14796694.5.1.19
• Languages: English
• ISSNs: 1479-6694

Abstract

Evaluation of: Strauss GM, Herndon JE 2nd, Maddaus MA et al. : Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol . 26, 5043––5051 (2008) . The CALGB 9633 study was designed to evaluate the efficacy of carboplatin and paclitaxel given in the adjuvant setting to patients with Stage IB non-small-cell lung cancer. Although interim analysis had shown clinical benefit, longer follow-up revealed lack of efficacy for this approach. We will examine the results of this trial in light of other positive adjuvant trials in patients with non-small-cell lung cancer.